Abivax announces the pricing of its initial public offering on the nasdaq global market

Paris, france / accesswire / october 20, 2023 / abivax sa (euronext paris:fr0012333284:abvx) (" abivax " or the " company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the pricing of its initial public offering on the nasdaq global market by way of a capital increase of 20,325,500 new ordinary shares (the " new shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of american depositary shares (" adss "), each representing the right to receive one ordinary share, in the united states (the " u.s. offering ") and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the united states to certain investors (the " european private placement " and together with the u.s. offering, the " global offering "). the offering price was set at $11.60 per ads in the u.s. offering and a corresponding offering price of €10.9864 per ordinary share based on an exchange rate of €1.00 = $1.0559 as published by the european central bank on october 19, 2023.
ABVX Ratings Summary
ABVX Quant Ranking